Community-based liver health assessment using noninvasive biomarkers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study aims to establish a community-based cohort of individuals at risk for liver disease, utilizing non-invasive biomarkers to assess liver disease severity. The study will recruit approximately 2,000 participants over four years, focusing on those with risk factors such as chronic liver disease, alcohol use disorder, type 2 diabetes, and obesity. Participants will undergo serum blood sampling, transient elastography, and qualitative interviews to evaluate liver health and potential lifestyle changes. The long-term follow-up will monitor liver and cardiovascular outcomes, providing valuable data for future interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients aged 18 years or over (male or female) with primary risk factor for liver disease:

  * Hazardous alcohol use (\>14 units/week for women, \>21 units/week for men)
  * Type 2 Diabetes
  * Obesity
  * Persistently elevated ALT with normal liver serology

Exclusion Criteria:

* Active malignancy at study enrolment
* Inability to provide informed consent for study enrolment
* Known presence of histologically proven liver disease prior to pilot pathway participation

Where it's running

• NIHR Nottingham Digestive Diseases Biomedical Research Unit
  Nottingham, Notts, United Kingdom Recruiting

Study contacts

• Principal investigator: Neil Guha, MRCP, PhD — University of Nottingham

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

• Switching to Zenagamtide from Semaglutide in adults with overweight or obesity, with or without type 2 diabetes

  This study tests whether adults who are already taking semaglutide can successfully switch to zenagamtide at different doses to see which dose works best.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07855133

• Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients

  This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.

  Recruiting Zhangzhou Municipal Hospital · Zhangzhou, Fujian · NCT07836088

• GUB-UCN2 in healthy, obese, and T2D adults: a first-in-human safety and pharmacology study

  This study tests GUB-UCN2 to see if it is safe and tolerable and how it behaves in the body in healthy adults, people with obesity, and people with obesity with or without type 2 diabetes.

  Recruiting Phase 1/2 Gubra A/S · Neuss · NCT07702890

• Two doses of CagriSema plus one dose of Semaglutide for weight loss in obesity with or without type 2 diabetes

  This study tests whether two doses of CagriSema, plus a dose of Semaglutide, help adults with obesity (with or without type 2 diabetes) lose weight.

  Recruiting Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 302 other locations · NCT07564414

• Semaglutide's effects on heart and muscle mass

  This project will use MRI scans and strength tests over 12 months to see if semaglutide changes body and heart muscle in adults starting the medication.

  Recruiting University of Alberta · Edmonton, Alberta · NCT07272837

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.